One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Oncology Care Model and Ripple Effects of Value-Based Care
doi : 10.1200/JCO-24-01983
2025, Volume 43 (2)
Will Prolyl Hydroxylase Inhibitors Supplant Erythropoiesis-Stimulating Agents and IV Iron in the Treatment of Chemotherapy-Induced Anemia?
doi : 10.1200/JCO-24-01694
Dual Immune Checkpoint Inhibition in Melanoma and PD-L1 Expression: The Jury Is Still Out
doi : 10.1200/JCO-24-01572
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
doi : 10.1200/JCO.24.00635
Association of Participation in Medicare's Oncology Care Model With Spending, Utilization, and Quality Outcomes Among Commercially Insured and Medicare Advantage Members
doi : 10.1200/JCO.24.00502
Efficacy and Safety of Roxadustat for Anemia in Patients Receiving Chemotherapy for Nonmyeloid Malignancies: A Randomized, Open-Label, Active-Controlled Phase III Study
doi : 10.1200/JCO.23.02742
Long-Term Risk of Subsequent Neoplasms in 5-Year Survivors of Childhood Neuroblastoma: A Dutch Childhood Cancer Survivor Study-LATER 3 Study
doi : 10.1200/JCO.23.01430
Sexual Health and Quality of Life in Patients With Low-Risk Early-Stage Cervical Cancer: Results From GCIG/CCTG CX.5/SHAPE Trial Comparing Simple Versus Radical Hysterectomy
doi : 10.1200/JCO.24.00440
Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study
doi : 10.1200/JCO.24.00171
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial
doi : 10.1200/JCO.24.00773
Randomized Phase III SIERRA Trial of 131 I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML
doi : 10.1200/JCO.23.02018
Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy
doi : 10.1200/JCO-24-01571
Erratum: ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma
doi : 10.1200/JCO-24-02561
Erratum: Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial
doi : 10.1200/JCO-24-02577
